Search results for "Large"

showing 10 items of 2197 documents

MALDI-TOF mass spectrometry identification of filamentous fungi in the clinical laboratory.

2014

Pôle MERS F. Dalle; International audience; This study aimed to validate the effectiveness of a standardised procedure for the MALDI-TOF mass spectrometry (MS)-based identification on a large sample of filamentous fungi routinely identified in university hospitals' laboratories. Non-dermatophyte filamentous fungi prospectively isolated in the routine activity of five teaching hospitals in France were first identified by conventional methods in each laboratory and then by MS in one centre. DNA sequence-based identification resolved discrepancies between both methods. In this study, of the 625 analysed filamentous fungi of 58 species, 501 (80%) and 556 (89%) were correctly identified by conve…

MALDI-TOFDermatologyBiologyMicrobiologyIdentification rateHospitals UniversitySpecies identificationHumansProspective StudiesArthrodermataceaefilamentous fungiFungiRoutine laboratoryGeneral MedicineSequence Analysis DNAUniversity hospitalMALDI-TOF Mass SpectrometryLarge sampleInfectious DiseasesLogistic Models[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologySpectrometry Mass Matrix-Assisted Laser Desorption-IonizationidentificationIdentification (biology)Franceroutine laboratory
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct

Conceptual design of the International Axion Observatory (IAXO)

2014

The International Axion Observatory (IAXO) will be a forth generation axion helioscope. As its primary physics goal, IAXO will look for axions or axion-like particles (ALPs) originating in the Sun via the Primakoff conversion of the solar plasma photons. In terms of signal-to-noise ratio, IAXO will be about 4-5 orders of magnitude more sensitive than CAST, currently the most powerful axion helioscope, reaching sensitivity to axion-photon couplings down to a few $\times 10^{-12}$ GeV$^{-1}$ and thus probing a large fraction of the currently unexplored axion and ALP parameter space. IAXO will also be sensitive to solar axions produced by mechanisms mediated by the axion-electron coupling $g_{…

MICROPICPhysics - Instrumentation and DetectorsPhotonaxionsParameter space7. Clean energyHigh Energy Physics - ExperimentDark Matter detectors (WIMPs axions etc.)High Energy Physics - Experiment (hep-ex)Observatoryetc.)Micropattern gaseous detectors (MSGC GEM THGEM RETHGEM MHSP MICROPIC MICROMEGAS InGrid etc)Detectors and Experimental TechniquesInstrumentationMathematical PhysicsPhysicsGEMsolar [axion]Dark Matter Detectors (Wimps Axions etc.)MicroMegas detectorX-ray detectorsInstrumentation and Detectors (physics.ins-det)Dark Matter detectors (WIMPs axions etc.); Large detector systems for particle and astroparticle physics; Micropattern gaseous detectors (MSGC GEM THGEM RETHGEM MHSP MICROPIC MICROMEGAS InGrid etc); X-ray detectors; Instrumentation; Mathematical PhysicssolarobservatoryMICROMEGASMHSPaxion-like particlesproposed experimentaxions ; dark matter detectors ; x-ray detectors ; Micropattern gaseous detectors ; large detector systems for particle and astroparticle physicsMicromegasX-ray detectorParticle physicsoptics [X-ray]FOS: Physical sciencesSuperconducting magnetMicropattern gaseous detectors (MSGCddc:610Axionactivity reportDark Matter detectors (WIMPssuperconductivity [magnet]etc)HelioscopeLarge detector systems for particle and astroparticle physicssensitivityInGridRETHGEMOrders of magnitude (time)axionLarge detector systems for particle and astroparticle physicTHGEMMicropattern Gaseous Detectors (MSGC Gem THGEM Rethgem MHSP Micropic Micromegas In Grid; etc)
researchProduct

Search for Magnetic Monopoles with the MoEDAL Forward Trapping Detector in 13 TeV Proton-Proton Collisions at the LHC

2017

MoEDAL is designed to identify new physics in the form of long-lived highly-ionising particles produced in high-energy LHC collisions. Its arrays of plastic nuclear-track detectors and aluminium trapping volumes provide two independent passive detection techniques. We present here the results of a first search for magnetic monopole production in 13 TeV proton-proton collisions using the trapping technique, extending a previous publication with 8 TeV data during LHC run-1. A total of 222 kg of MoEDAL trapping detector samples was exposed in the forward region and analysed by searching for induced persistent currents after passage through a superconducting magnetometer. Magnetic charges excee…

Magnetic monopolesProtonMagnetismPhysics beyond the Standard ModelGeneral Physics and Astronomy01 natural sciences7. Clean energyHigh Energy Physics - Experimentlaw.inventionCOLLIDERHigh Energy Physics - Experiment (hep-ex)High Energy Physics - Phenomenology (hep-ph)STOPPING-POWERlawPhysics02 Physical SciencesLarge Hadron ColliderSTABLE MASSIVE PARTICLESPhysicsMagnetismDrell–Yan processhep-phPersistent currents3. Good healthHigh Energy Physics - PhenomenologyPhysical SciencesELECTROWEAK MONOPOLEParticle Physics - ExperimentGeneral PhysicsMagnetometerPhysics MultidisciplinaryMagnetic monopoleFOS: Physical sciencesNuclear track detector114 Physical sciencesNuclear physicsPhysics and Astronomy (all)Tellurium compoundsHigh energy physics Magnetism Magnetometers Highly ionizing particles Magnetic charges Magnetic monopoles Nuclear track detector Passive detection Persistent currents Proton proton collisions Trapping techniques Tellurium compounds0103 physical sciencesHigh energy physics010306 general physicsColliderIONIZING PARTICLESScience & TechnologyProton proton collisionshep-ex010308 nuclear & particles physicsMagnetometers Highly ionizing particlesMagnetic chargesTrapping techniquesPassive detectionSTATES
researchProduct

Direct imaging of high frequency multimode spin wave propagation in cobalt iron waveguides using X ray microscopy beyond 10 GHz

2020

MagnonicsMulti-mode optical fiberMaterials sciencebusiness.industryMagnetismX-raychemistry.chemical_elementLarge scale facilities for research with photons neutrons and ionsCondensed Matter PhysicschemistrySpin waveMicroscopyOptoelectronicsGeneral Materials SciencebusinessNanoscopic scaleCobalt
researchProduct

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

2021

Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa‐cel in the standard‐of‐care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa‐cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded accor…

Male0301 basic medicine:aminoácidos péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de antígenos::receptores de antígenos de linfocitos T [COMPUESTOS QUÍMICOS Y DROGAS]Cancer Researchnon‐Hodgkin's lymphomaBest Overall Responsehematological cancer:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Non- Hodgkin's lymphomaGastroenterology0302 clinical medicineMedicine research:Other subheadings::/therapeutic use [Other subheadings]CàncerB-cell lymphomaRC254-282CancerOriginal ResearchReceptors Chimeric AntigenNeoplasms. Tumors. Oncology. Including cancer and carcinogensnon&#8208Standard of CareMiddle AgedPatologiaHodgkin&aposProgression-Free SurvivalCytokine release syndromeclinical cancer researchOncology:neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES]030220 oncology & carcinogenesisCytokinesFemaleLymphoma Large B-Cell Diffusenon-Hodgkin's lymphomamedicine.medical_specialtyReceptors Antigen T-CellCèl·lules B - Tumors - Tractament:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Investigació mèdicaReal world evidence03 medical and health sciencess lymphoma:Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma Non-Hodgkin::Lymphoma B-Cell::Lymphoma Large B-Cell Diffuse [DISEASES]Refractoryclinical observationsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingLeukapheresis:Amino Acids Peptides and Proteins::Proteins::Membrane Proteins::Receptors Cell Surface::Receptors Immunologic::Receptors Antigen::Receptors Antigen T-Cell [CHEMICALS AND DRUGS]AgedRetrospective Studies:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryTeràpia cel·lularClinical Cancer ResearchLeukapheresismedicine.diseaseMalaltia de HodgkinNon-Hodgkin's lymphomaLymphoma030104 developmental biologyHodgkin's diseaseNeoplasm Recurrence LocalbusinessCancer Medicine
researchProduct

The relationship between Polypharmacy and Trajectories of Cognitive Decline in People with Dementia: a large representative cohort study

2019

Polypharmacy, defined through the number of medications prescribed, has been linked to a range of adverse health outcomes in people with dementia. It is however unclear whether a numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive decline. We aimed to test associations between polypharmacy and both short-term (six months) and long-term (three years) cognitive trajectories in patients with incident dementia. Using data from a large mental health and dementia care database in South London, a cohort of 12,148 patients (mean age = 80.7 years, 61.1% female, mean MMSE = 18.6) clinically diagnosed with dementia was identified. We determined the number of medi…

Male0301 basic medicineGerontologyAgingCognitive declineBiochemistryCohort Studies03 medical and health sciencesCognitionCommunity care0302 clinical medicineEndocrinologyA large representative cohort study.- Experimental gerontology cilt.120 ss.62-67 2019 [Soysal P. Perera G. Isik A. Onder G. Petrovic M. Cherubini A. Maggi S. Shetty H. Molokhia M. Smith L. et al. -The relationship between polypharmacy and trajectories of cognitive decline in people with dementia]mental disordersGeneticsmedicineHumansDementiaCognitive DysfunctionCognitive declineassociations between polypharmacyMolecular BiologyAgedAged 80 and overPolypharmacypeople with dementia.Mini–Mental State Examinationmedicine.diagnostic_testbusiness.industryCognition; Cognitive decline; Community care; Dementia; PolypharmacyCognitionlong-term (three years)Cell BiologyMental Status and Dementia Testsmedicine.diseaseComorbidity030104 developmental biologyCohortPolypharmacyFemaleDementiabusinessshort-term (six months)030217 neurology & neurosurgeryCohort study
researchProduct

Chronic exercise impairs nitric oxide pathway in rabbit carotid and femoral arteries

2018

KEY POINTS: Some of the beneficial effects of exercise in preventing vascular related diseases are mediated by the enhancement of endothelial function where the role of nitric oxide (NO) is well documented, although the relevance of calcium activated potassium channels is not fully understood. The impact of oxidative stress induced by training on endothelial function remains to be clarified. By evaluating different endothelial vasodilator pathways on two vascular beds in a rabbit model of chronic exercise, we found a decreased NO bioavailability and endothelial nitric oxide synthase expression in both carotid and femoral arteries. Physical training induced carotid endothelial dysfunction as…

Male0301 basic medicinemedicine.medical_specialtyPhysiologyVasodilationFemoral artery030204 cardiovascular system & hematologyNitric OxideApaminNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEnosPhysical Conditioning AnimalInternal medicinemedicine.arterymedicineAnimalsLarge-Conductance Calcium-Activated Potassium ChannelsEndothelial dysfunctionExercisebiologybiology.organism_classificationmedicine.diseaseCalcium-activated potassium channelFemoral ArteryOxidative StressCarotid Arteries030104 developmental biologyEndocrinologychemistryNitric Oxide PathwayEndothelium VascularRabbitsThe Journal of Physiology
researchProduct

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome

2010

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047).…

MaleAged; Amino Acid Sequence; Animals; Disease Progression; Epidemiologic Methods; Female; Genetic Predisposition to Disease; Genotype; Humans; LDL-Receptor Related Proteins; Leukemia Lymphocytic Chronic B-Cell; Lymphoma; Male; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Polymorphism Single Nucleotide; Prognosis; Sequence Alignment; SyndromeGenotypeLymphomaMolecular Sequence DataLRP4genetics/metabolismRichter syndrome; chronic lymphocytic leukemia; LRP4 genePolymorphism Single NucleotideAnimalsHumansGenetic Predisposition to DiseaseAmino Acid SequenceChronicPolymorphismLDL-Receptor Related ProteinsAgedLeukemiaLRP4 geneB-CellSingle NucleotideSyndromeMiddle AgedPrognosisRichter syndrome.Leukemia Lymphocytic Chronic B-Cellsingle nucleotide polimorphismLymphocyticdiffuse large B cell lymphomaNeoplasm ProteinsAged Amino Acid Sequence Animals Disease Progression Epidemiologic Methods Female Genetic Predisposition to Disease Genotype Humans LDL-Receptor Related Proteins; genetics/metabolism Leukemia; Lymphocytic; Chronic; B-Cell; genetics/metabolism Lymphoma; genetics/metabolism Male Middle Aged Molecular Sequence Data Neoplasm Proteins; genetics/metabolism Polymorphism; Single Nucleotide Prognosis Sequence Alignment SyndromeSettore MED/15 - MALATTIE DEL SANGUERichter syndrome; chronic lymphocytic leukaemia; diffuse large B cell lymphoma; single nucleotide polimorphism; LRP4Disease Progressionchronic lymphocytic leukemiaFemaleRichter syndromeEpidemiologic MethodsSequence Alignmentchronic lymphocytic leukaemia
researchProduct

Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain.

2004

Background:  Most studies show a steep increase in asthma prevalence in the last decades, although few studies had applied the same methodology. Recent reports point out the possibility that the epidemic has come to an end. We have studied the prevalence of asthma in a very large sample of children, repeating the study eight years apart. Methods:  Repeated cross-sectional studies using the International Study of Asthma and Allergies in Childhood (ISAAC) protocol in a sample of Spanish schoolchildren 6–7 (parent-reported) and 13–14 (self-reported) years old in 1994–95 (phase I) and 2002–2003 (phase III). The number of participants was 42 417 in phase I and 42 813 in phase III. The participat…

MaleAllergyPediatricsmedicine.medical_specialtyAdolescentCross-sectional studyImmunologySurveys and QuestionnairesmedicinePrevalenceImmunology and AllergyHumansChildAsthmaSchool age childbusiness.industryEstudio transversalmedicine.diseaseAsthmaLarge sampleCross-Sectional StudiesEl NiñoLung diseaseSpainFemalebusinessAllergy
researchProduct